Tanaka, Sakae http://orcid.org/0000-0001-9210-9414
Tanaka, Yoshiya
Article History
Received: 26 June 2020
Accepted: 19 September 2020
First Online: 18 October 2020
Change Date: 17 December 2020
Change Type: Correction
Change Details: In the original publication of the article, the title of Table was published incorrectly. The correct title should read as “Baseline patient demographics and characteristics in DESIRABLE trial. Adopted from Reference with permission”.
Compliance with ethical standards
:
: Sakae Tanaka received consulting fees, speaking fees, and/or honoraria from Asahi Kasei Pharma Co., Daiichi-Sankyo Co., Ltd., Mitsubishi-Tanabe Pharma Co., and Teijin Pharma, Ltd. and research grants from Astellas Pharma Inc., Asahi Kasei Pharma Co., AYUMI Pharmaceutical Co., Chugai Pharmaceutical Co., Ltd., Daiichi-Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc., Stryker Japan K.K., Taisho Toyama Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. Yoshiya Tanaka received speaking fees and/or honoraria from Daiichi-Sankyo Co. Ltd., Eli Lilly Japan K.K., Novartis, YL Biologics Ltd., Bristol-Myers Squibb Co., Eisai Co. Ltd., Chugai Pharmaceutical Co. Ltd., Abbvie, Astellas Pharma Inc., Pfizer Japan Inc., Sanofi K.K., Asahi Kasei Pharma Inc., GSK, Mitsubishi-Tanabe Pharma Co., Gilead Sciences Inc., Janssen Pharmaceutical K.K., and received research grants from Abbvie, Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co. Ltd., Asahi Kasei Pharma Inc., Eisai Co. Ltd., Takeda Pharmaceutical Co. Ltd., Daiichi-Sankyo Co. Ltd.